window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

personalised medicine

  • Digital & Data,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AI model cuts radiopharmaceutical dose mapping to seconds in prostate cancer study

    A new AI model has generated patient-specific radiation dose-rate maps [...]

    August 5, 2026
  • Genomics and sequencing,Manufacturing & Supply Chain,Research & Development

    DNA Script and GE HealthCare awarded up to $26M for DNA bioproduction programme

    DNA Script and GE HealthCare are developing an automated platform [...]

    August 4, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Genomics and sequencing,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Medicus Pharma gets UAE approval to start genomics-guided endometriosis study

    Medicus Pharma has received authorisation from the UAE Department of [...]

    July 31, 2026
  • Central Nervous System,Research & Development

    Brain network dynamics may better explain psychiatric symptoms than diagnoses

    Rutgers researchers found that changes in brain network dynamics were [...]

    July 22, 2026
  • Advanced Therapies,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma

    Enterome Phase 1/2 data show EO2463-induced CD8 T-cell expansion was [...]

    July 22, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Medicus files IND for genomics-enabled Phase 2 endometriosis trial

    Medicus Pharma has submitted an investigational new drug application in [...]

    June 11, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    23andMe study links genetics to GLP-1 weight loss outcomes and side effects

    This Nature-published study from the 23andMe Research Institute identifies genetic [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Inaphaea BioLabs boosts precision oncology with new partnerships, advanced tumour models, and digital patient avatars

    Inaphaea BioLabs, the translational contract research organisation (CRO) of ValiRx [...]

    May 5, 2026
  • Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Abu Dhabi Biobank expands access to cord blood banking through NMC Healthcare partnership

    Abu Dhabi Biobank has partnered with NMC Healthcare to expand [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adva Biotechnology and Autolomous launch digital pioneer program for scalable autologous cell therapy manufacturing

    Adva Biotechnology Ltd. and Autolomous Ltd. have announced a strategic [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top